6 months ago
PFE
AnalystsEvan David SeigermanEvan David Seigerman's Stock Forecasts
AnalystsEvan David Seigerman
Sectors:
Industries:
Analyst Ranking
Top 25%
#1107 out of 4563 analysts
Average Return
+11.98%
Win Rate
44%7 out of 16
Risk vs Reward
Poor
Good
Evan David Seigerman's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Candel Therapeutics IncCADL | +278.13% | $1.60 | $6.05 | 2023-05-14 - 2024-04-24 | Buy |
Eli Lilly & CoLLY | +81.93% | $306.82 | $558.19 | 2022-09-05 - 2023-09-05 | Buy |
Merck & Co IncMRK | +23.52% | $102.82 | $127.00 | 2023-10-26 - 2024-04-24 | Buy |
Morphic Holding IncMORF | +23.12% | $22.49 | $27.69 | 2023-09-27 - 2024-04-24 | Buy |
Regeneron Pharmaceuticals IncREGN | +17.96% | $820.00 | $967.24 | 2023-03-23 - 2024-03-22 | Buy |
Evan David Seigerman Analyst Color
Get additional color on Evan David Seigerman's coverage of popular stocks
Evan David Seigerman's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Novo Nordisk A SNVO | 1 | Buy | $163.00 | +29.20% | Initiates Coverage On | 13 days ago |
Regeneron Pharmaceuticals IncREGN | 3 | Buy | $1,082.00 | +19.35% | Maintains | 3 months ago |
Abbvie IncABBV | 1 | Buy | $195.00 | +16.21% | Maintains | 3 months ago |
Amgen IncAMGN | 2 | Buy | $326.00 | +19.41% | Upgrades | 4 months ago |
Merck & Co IncMRK | 1 | Buy | $132.00 | +3.94% | Upgrades | 6 months ago |
Pfizer IncPFE | 3 | Buy | $33.00 | +25.62% | Maintains | 6 months ago |
Mirati Therapeutics IncMRTX | 4 | Hold | $72.00 | +22.66% | Maintains | 7 months ago |
Structure Therapeutics IncGPCR | 1 | Buy | $83.00 | +127.83% | Maintains | 7 months ago |
Morphic Holding IncMORF | 2 | Buy | $52.00 | +87.79% | Maintains | 7 months ago |
Candel Therapeutics IncCADL | 1 | Buy | $3.00 | -50.41% | Maintains | a year ago |
Replimune Group IncREPL | 1 | Buy | $70.00 | N/A | Maintains | a year ago |
Eli Lilly & CoLLY | 1 | Buy | $396.00 | N/A | Maintains | 2 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.